In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Eyegate Pharmaceuticals Inc. (NASDAQ:EYEG) reported that Ipsa (innoven Partenaires S.a.) has picked up 1,549,650 of common stock as of 2017-06-16.
The acquisition brings the aggregate amount owned by Ipsa (innoven Partenaires S.a.) to a total of 1,549,650 representing a 9.5% stake in the company.
For those not familiar with the company, Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
A glance at Eyegate Pharmaceuticals Inc. (NASDAQ:EYEG)’s key stats reveals a current market capitalization of $14.34 Million based on $10.94 Million shares outstanding and a price at last close of $1.29 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-09-15, From picked up 15,000 at a purchase price of $1.49. This brings their total holding to 139,965 as of the date of the filing.
On the sell side, the most recent transaction saw Ventech unload 4,419 shares at a sale price of $2.80. This brings their total holding to 1,431,814.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an Eyegate Pharmaceuticals Inc. (NASDAQ:EYEG) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.